St. Mary’s Medical Center is the First Hospital in Florida to Treat Stroke Patients with Novel TIGERTRIEVERÔ Stroke Device

St. Mary’s Medical Center is the first hospital in Florida to remove a blood clot in the brain using Rapid Medical’s new TIGERTRIEVER device—the only clot removal tool that is adjustable inside the brain. TIGERTRIEVER enables neuro interventionalists to better remove blood clots and restore blood flow to the brain following a stroke—a condition that devastates 800,000 Americans annually. Dr. Ali Malek, medical director of the comprehensive stroke center at the hospital, performed the procedure.

“This new technology gives our team an even better opportunity to capture clots that form in the brain so we can treat someone having a stroke as quickly as possible,” said Dr. Ali Malek. “Using the TIGERTRIEVER is a breakthrough in our community, and we look forward to providing the level of care needed for patients who come to our comprehensive stroke center.”

TIGERTRIEVER is the first and only adjustable clot retriever, providing physicians with greater control and adaptability to varying patient anatomy and circumstances. While viewing the device under x-ray guidance, physicians can adjust it to match the vessel size and better capture the clot.

“This is just another example as to why St. Mary’s Medical Center continues to be at the forefront of neurologic care when it comes to treating strokes,” said Cynthia McCauley, chief executive officer of St. Mary’s Medical Center & Palm Beach Children’s Hospital. “We look forward to using this new technology to treat our patients so they can receive the quality care they deserve when they are brought to our hospital.”

St. Mary’s Medical Center is an award-winning Comprehensive Stroke Center providing quality care in stroke prevention, stroke management, and stroke rehabilitation. Our center is equipped with some of the latest diagnostic and therapeutic advances to quickly and accurately diagnose and treat stroke patients. Patients benefit from a range of comprehensive medical, surgical and minimally invasive treatment options, as well as access to clinical trials and research.

For more information on our comprehensive services, go to www.stmarysmc.com or call 561-844-6300.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.